Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- DWTI’s Antiplatelet Agent Enters Late PII Stage
January 11, 2012
- Bayer Submits Rivaroxaban in EU, US for Add’l Indication
January 11, 2012
- Top Managements of Pharmaceutical Companies Express Complaints for Additional Price Cut for Long-Listed Drugs
January 10, 2012
- Bayer Yakuhin to Promote Long-Listed Products Without Mediation by MRs
January 10, 2012
- Bayer Yakuhin President Guth Says Marketing Success of 2 Strategic Products Key Focus
January 10, 2012
- Toho HD Chairman Matsutani Showed Enthusiasm for 3rd Round of Distribution Improvement Talks
January 10, 2012
- Takeda and Osaka Univ. Establish Joint Research Chair for Nano-particle Vaccines
January 10, 2012
- Astellas Terminates License Agreement for VIBATIV Injection
January 10, 2012
- Asahi Kasei Pharma Launches Flivas in South Korea through Dong-A
January 10, 2012
- Pharmacist Survey Shows Meiji Seika Pharma Rise to 3rd Rank for “Memorable” MRs
January 6, 2012
- Deutsche Securities Report Says Patent Cliff Concerns Scarce for MTPC
January 6, 2012
- AZ President Hudson Says Development of Japanese Leaders One of Key Company Issues
January 6, 2012
- AZ to Utilize E-detailing, Optimize According to Product
January 6, 2012
- Top Execs Stress Importance of Emerging Markets, Compliance in New Year's Addresses
January 6, 2012
- Toray to Take Equity Stake in Mitsui’s Subsidiary
January 6, 2012
- Seikagaku Changes Sales Partner for Supartz in US
January 6, 2012
- Astellas Directed to Suspend Export of Gaster to South Korea Due to Use of Unapproved API
January 6, 2012
- Meiji Seika Pharma Submits Application for ME2080 to Treat Dravet’s Syndrome
January 6, 2012
- Tivozanib Significantly Improves PFS Compared to Sorafenib in RCC: Astellas
January 6, 2012
- Takara Bio, Mie Univ. to Collaborate in Clinical Trial of Cancer Treatment
January 6, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…